Comparison
Exenatide vs. MGF (Mechano Growth Factor)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
141758-74-9
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Molecular weight
4186.6 g/mol
2867.2 g/mol
Half-life
2.4 h
0.1 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSYQPPSTNKNTKSQRRKGSTFEERKMechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
4
of which in humans
4
0
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
1